|
| 37871306 | Blinatumomab consolidation post-autologous stem cell transplantation in patients with diffuse large B-cell lymphoma. | Blood Adv | 2024 |
| 38071272 | Belumosudil and ruxolitinib combination for treatment of refractory chronic graft-versus-host disease. | Bone Marrow Transplant | 2024 |
| 36008121 | First-in-Humans Evaluation of Safety and Dosimetry of <sup>64</sup>Cu-LLP2A for PET Imaging. | J Nucl Med | 2023 |
| 37597685 | Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell Transplantation. | Transplant Cell Ther | 2023 |
| 37914932 | Epigenetic regulation during cancer transitions across 11 tumour types. | Nature | 2023 |
| 37798328 | An "off-the-shelf" CD2 universal CAR-T therapy for T-cell malignancies. | Leukemia | 2023 |
| 37953814 | Duvelisib for Critically Ill Patients With Coronavirus Disease 2019: An Investigator-Initiated, Randomized, Placebo-Controlled, Double-Blind Pilot Trial. | Open Forum Infect Dis | 2023 |
| 37744381 | Baricitinib with cyclosporine eliminates acute graft rejection in fully mismatched skin and heart transplant models. | Front Immunol | 2023 |
| 37868029 | Immune Adjuvant Therapy With Interleukin-7 in a Lymphopenic Patient With Aplastic Anemia and Mucormycosis. | Crit Care Explor | 2023 |
| 37250913 | Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide. | Ther Adv Hematol | 2023 |
| 37339484 | Genomic landscape of TP53-mutated myeloid malignancies. | Blood Adv | 2023 |
| 37069359 | Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. | Nat Med | 2023 |
| 37399471 | Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc. | Blood Adv | 2023 |
| 37034289 | Apolipoprotein M Attenuates Anthracycline Cardiotoxicity and Lysosomal Injury. | JACC Basic Transl Sci | 2023 |
| 37327120 | Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor. | Blood Adv | 2023 |
| 36922593 | The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. | Nature | 2023 |
| 36477272 | S100A9 upregulated by IFNGR signaling blockade functions as a novel GVHD suppressor without compromising GVL in mice. | Blood | 2023 |
| 36779841 | Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma. | Cancer Res | 2023 |
| 36711871 | Genomic landscape of <i>TP53</i> -mutated myeloid malignancies. | medRxiv | 2023 |
| 36804933 | A Multicenter Phase 2 Clinical Trial of 10-Day Decitabine, Dose-Escalated Donor Lymphocyte Infusion, and Ruxolitinib for Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Cell Transplantation. | Transplant Cell Ther | 2023 |
| 36563336 | Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells. | Blood | 2023 |
| 36860569 | A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome. | Front Neurol | 2023 |
| 34304247 | Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFR. | Leukemia | 2022 |
| 35709710 | Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome Progression. | Blood Cancer Discov | 2022 |
| 35437311 | Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program. | Bone Marrow Transplant | 2022 |
| 35697686 | A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity. | Nat Commun | 2022 |
| 35366991 | Mouse models of graft-versus-host disease. | Methods Cell Biol | 2022 |
| 35422095 | CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells. | Leukemia | 2022 |
| 36969740 | Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis. | Cancer Res Commun | 2022 |
| 35895896 | Proteomic and phosphoproteomic landscapes of acute myeloid leukemia. | Blood | 2022 |
| 36054756 | Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia. | Am J Hematol | 2022 |
| 35878743 | Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving Perspective. | Transplant Cell Ther | 2022 |
| 35877996 | The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis. | Blood | 2022 |
| 36048456 | Assessment of Pretreatment and Posttreatment Evolution of Neurofilament Light Chain Levels in Patients Who Develop Immune Effector Cell-Associated Neurotoxicity Syndrome. | JAMA Oncol | 2022 |
| 35319225 | Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19. | J Virol | 2022 |
| 35014164 | Liposomal phytohemagglutinin: In vivo T-cell activator as a novel pan-cancer immunotherapy. | J Cell Mol Med | 2022 |
| 34996933 | Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival. | Sci Rep | 2022 |
| 34996889 | Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. | Nat Commun | 2022 |
| 34873300 | Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells. | Leukemia | 2022 |
| 35236053 | Decitabine salvage for <i>TP53</i>-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy. | Haematologica | 2022 |
| 35196021 | Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia. | Sci Transl Med | 2022 |
| 35019859 | Genetic and Transcriptional Contributions to Relapse in Normal Karyotype Acute Myeloid Leukemia. | Blood Cancer Discov | 2022 |
| 34555850 | Machine learning-based scoring models to predict hematopoietic stem cell mobilization in allogeneic donors. | Blood Adv | 2022 |
| 34797911 | Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. | Blood | 2022 |
| 34794373 | Increased early mortality after fludarabine and melphalan conditioning with peripheral blood grafts in haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. | Leuk Lymphoma | 2022 |
| 32929488 | Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. | Blood | 2021 |
| 33843914 | Highlights in chronic graft-vs-host disease from the 62nd American Society of Hematology Annual Meeting and Exposition: commentary. | Clin Adv Hematol Oncol | 2021 |
| 33704937 | Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers. | N Engl J Med | 2021 |
| 34588522 | A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma. | Sci Rep | 2021 |
| 34586539 | In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [<sup>18</sup>F]FDG and [<sup>64</sup>Cu]Cu-LLP2A PET. | EJNMMI Res | 2021 |